HM Payson & Co’s Axonics, Inc. Common Stock AXNX Stock Holding History

HM Payson & Co’s Portfolio AXNX Stock Details AXNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1	Closed	–	–	1099
2022 Q2	$0	Buy	+1	New	+$55	﹤0.01%	1165

Other funds holding AXNX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

HM Payson & Co's AXNX Position: Q3 2022 in Review

HM Payson & Co sold out of Axonics, Inc. Common Stock (AXNX) in Q3 2022, closing a stake of 1 share.

HM Payson & Co first reported a position in AXNX in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 230 funds tracked by Wall St. Rank hold AXNX as of Q3 2022.

HM Payson & Co reported no remaining Axonics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
HM Payson & Co sold 1 Axonics, Inc. Common Stock share in Q3 2022.
HM Payson & Co first reported a position in Axonics, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
HM Payson & Co's Axonics, Inc. Common Stock position peaked at $0 in Q2 2022.
230 funds tracked by Wall St. Rank held Axonics, Inc. Common Stock as of Q3 2022.

Based on HM Payson & Co's 13F filing for Q3 2022, filed 25 Oct 2022.